Physician profile
Timothy Muchayi
NPI 1073743902
$3,372.59
in general payments reported to CMS, 2019-2025
24 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $48.25 · 2021: $29.93 · 2022: $503 · 2023: $440 · 2024: $976 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.51 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $498.63 | 2022-2025 | |
| Vifor Pharma, INC. | $404.43 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $388.41 | 2022-2025 | Farxiga, Lokelma, Wainua |
| Calliditas Therapeutics US INC. | $379.11 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $232.17 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $207.64 | 2025 | Ozempic, Rybelsus |
| Mallinckrodt Hospital Products INC. | $169.73 | 2023-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $129.41 | 2024-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.65 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $120.81 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $118.12 | 2022-2023 | Krystexxa |
| Amgen INC. | $99.90 | 2024-2025 | Tavneos, Repatha, Repatha |
| Fresenius USA Marketing, INC. | $84.71 | 2024-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $81.47 | 2023-2025 | |
| Glaxosmithkline, LLC. | $79.46 | 2021-2023 | Benlysta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $76.54 | 2025 | |
| Mallinckrodt Enterprises LLC | $25.39 | 2019 | |
| Cycle Pharmaceuticals INC | $25.00 | 2024 | Tiopronin |
| Alnylam Pharmaceuticals INC. | $24.73 | 2025 | Oxlumo |
| Apellis Pharmaceuticals, INC. | $22.27 | 2025 | Empaveli |
| Nxstage Medical, INC. | $21.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.78 | 2025 | |
| Xeris Pharmaceuticals, INC. | $20.32 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Muchayi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.